ABT Earnings & Financial Statements
Abbott Laboratories
$102.97
+$0.36(+0.35%)
54
Overall
90
Value
27
Tech
47
Quality
Market Cap
$178.18B
Volume
7.27M
52W Range
$81.97 - $133.34
Target Price
$120.74
ABT earnings and financial statements: Abbott Laboratories's income statement, balance sheet and cash flow statement, annual and quarterly.
ABT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B |
| Cost of revenue | $19.32B | $18.71B | $17.98B | $19.14B | $18.54B |
| Operating income | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B |
| EBITDA | $12.07B | $10.79B | $10.54B | $12.13B | $12.28B |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B |
| EPS (diluted) | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $86.71B | $81.41B | $73.21B | $74.44B | $75.17B |
| Total liabilities | $26.39B | $26.78B | $34.39B | $37.53B | $39.17B |
| Shareholders’ equity | $52.13B | $47.66B | $38.60B | $36.69B | $35.80B |
| Cash and equivalents | $8.52B | $7.62B | $6.90B | $9.88B | $9.80B |
| Long-term debt | $9.90B | $12.63B | $13.60B | $14.52B | $17.30B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $9.57B | $8.56B | $7.26B | $9.58B | $10.53B |
| Capital expenditure | -$2.17B | -$2.21B | -$2.20B | -$1.78B | -$1.89B |
| Free cash flow | $7.39B | $6.35B | $5.06B | $7.80B | $8.65B |
| Dividends paid | $4.12B | $3.84B | $3.56B | $3.31B | $3.20B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABT | $102.97 | +0.4% | 7.27M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |